Michael von Wagner
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Berg T, Alshuth U, Martus P, Spengler U, Klinker H, Kallinowski B, Schmidt W, Pape G, Rasenack J, Goeser T, Buggisch P, Gerlach T, Heintges T, Sarrazin C, Nasser S, von Wagner M, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-97.
Apr 1, 2006Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Apr 1, 2006Gastroenterology 2006; 130:1086-97
Berg Thomas, Alshuth Ulrich, Martus Peter, Spengler Ulrich, Klinker Hartwig, Kallinowski Birgit, Schmidt Wolfgang E, Pape Gerd R, Rasenack Jens, Goeser Tobias, Buggisch Peter, Gerlach Tilman, Heintges Tobias, Sarrazin Christoph, Nasser Samer, von Wagner Michael, Zeuzem Stefan
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
von Wagner M, Herrmann E, Häussinger D, Bernsmeier C, Bergk A, Heintges T, Rasenack J, Hinrichsen H, Berg T, Huber M, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7.
Aug 1, 2005Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
Aug 1, 2005Gastroenterology 2005; 129:522-7
von Wagner Michael, Herrmann Eva, Häussinger Dieter, Bernsmeier Christine, Bergk Alexandra, Heintges Tobias, Rasenack Jens, Hinrichsen Holger, Berg Thomas, Huber Miriam, Zeuzem Stefan